Anastrozole (Arimidex) is an aromatase inhibitor widely prescribed for hormone receptor-positive breast cancer in postmenopausal women. Whilst generally well-tolerated, questions arise about its potential effects on liver health, including concerns about arimidex and fatty liver disease. Understanding the relationship between anastrozole and hepatic function is important for patients undergoing long-term treatment. This article examines the evidence linking anastrozole to liver problems, explains how to recognise potential symptoms, and provides practical guidance on monitoring and maintaining liver health during treatment, in line with UK clinical guidance from NICE, the MHRA, and the BNF.

What Is Anastrozole (Arimidex) and How Does It Work?

Anastrozole (brand name Arimidex) is an aromatase inhibitor licensed in the UK for the treatment of hormone receptor-positive breast cancer in postmenopausal women. According to the Medicines and Healthcare products Regulatory Agency (MHRA) Summary of Product Characteristics (SmPC), it works by blocking the enzyme aromatase, which is responsible for converting androgens into oestrogen in peripheral tissues. By reducing circulating oestrogen levels, anastrozole helps to slow or stop the growth of oestrogen-dependent breast cancer cells.

The medication is typically prescribed as adjuvant therapy following surgery or radiotherapy, or as first-line treatment for advanced breast cancer. The standard dose is 1 mg taken orally once daily. Treatment duration often extends for five years or longer, depending on individual clinical circumstances and NICE guidance (NICE NG101: Early and locally advanced breast cancer).

Mechanism of action: Unlike tamoxifen, which blocks oestrogen receptors, anastrozole prevents oestrogen production at its source. This distinction is important because it means the drug affects overall oestrogen levels throughout the body, which can have implications for various organ systems, including bone density and lipid metabolism. The British National Formulary (BNF) notes that hypercholesterolaemia is a recognised adverse effect.

Important prescribing information: Anastrozole is indicated for postmenopausal women only. No dose adjustment is required for renal impairment. The SmPC advises caution in patients with severe hepatic impairment, though no specific dose reduction is recommended. Do not co-administer anastrozole with tamoxifen or oestrogen-containing therapies, as these reduce its efficacy.

Whilst anastrozole is generally well-tolerated, it can affect liver function in some patients. The MHRA notes that hepatic adverse reactions have been reported, though serious liver problems remain uncommon. Understanding how anastrozole works helps patients and healthcare professionals monitor for potential side effects, including those affecting the liver, and make informed decisions about ongoing treatment and surveillance.

Recognising Liver Problems Whilst Taking Anastrozole

Liver-related adverse effects associated with anastrozole can range from mild, asymptomatic elevations in liver enzymes to more significant hepatic dysfunction, though severe cases are rare. The MHRA Summary of Product Characteristics (SmPC) for anastrozole lists hepatitis as an uncommon adverse reaction (affecting between 1 in 100 and 1 in 1,000 patients). Elevations in liver enzymes (ALT, AST, alkaline phosphatase, gamma-GT) can occur and are often mild; the frequency varies by individual test.

The evidence linking anastrozole to fatty liver disease (hepatic steatosis) specifically is limited and inconclusive. There is no clearly established causal relationship in the current literature. However, changes in hormone levels and metabolism induced by aromatase inhibition may theoretically influence hepatic lipid metabolism. Some patients may experience:

• Elevated liver enzymes (ALT, AST, alkaline phosphatase) detected on routine blood tests

• Jaundice – yellowing of the skin or whites of the eyes

• Dark urine or pale-coloured stools

• Persistent fatigue beyond usual cancer treatment tiredness

• Upper abdominal discomfort or pain, particularly in the right upper quadrant

• Unexplained nausea or loss of appetite

• Itching (pruritus) without an obvious skin cause

It is important to note that many patients taking anastrozole will have no liver symptoms whatsoever. When liver enzyme abnormalities do occur, they are often detected through routine monitoring blood tests before symptoms develop. Pre-existing liver conditions, including non-alcoholic fatty liver disease (NAFLD), obesity, diabetes, or concurrent medications may increase the risk of hepatic complications during anastrozole therapy. Risk factors for NAFLD are described in NICE guideline NG49 (Non-alcoholic fatty liver disease). Your oncology team should be aware of any pre-existing liver conditions before starting treatment.

Managing Liver Health During Anastrozole Treatment

Proactive monitoring is essential for maintaining liver health whilst taking anastrozole. Baseline liver function tests (LFTs) are usually performed before starting treatment. Periodic follow-up LFTs are arranged at intervals determined by your oncologist based on individual risk factors and local oncology protocols. NICE guidance on early and locally advanced breast cancer (NG101) recommends regular clinical review during endocrine therapy, but does not specify routine LFT monitoring intervals for anastrozole; decisions are made on a case-by-case basis.

Lifestyle modifications can support liver health during treatment:

• Maintain a healthy weight – obesity is a significant risk factor for fatty liver disease independent of medication

• Follow a balanced diet rich in vegetables, fruits, whole grains, and lean proteins whilst limiting saturated fats and refined sugars

• Limit alcohol consumption – the NHS recommends not regularly drinking more than 14 units per week, spread over three or more days, to keep health risks low

• Stay physically active – regular exercise helps maintain healthy weight and improves insulin sensitivity, both protective against fatty liver

• Manage comorbidities – optimise control of diabetes, high cholesterol, and hypertension

• Review all medications – inform your GP and oncologist about all prescribed and over-the-counter medications, as some can affect the liver

Medication interactions and cautions: Anastrozole is metabolised in the liver, and concurrent use of other hepatotoxic medications may increase risk. Do not take anastrozole with tamoxifen or oestrogen-containing therapies, as these reduce its effectiveness. If you use paracetamol, do not exceed 4 grams (eight 500 mg tablets) in 24 hours for adults; if you have liver disease or are uncertain, seek advice from your pharmacist or doctor. Discuss any herbal supplements with your healthcare team, as some (such as green tea extract or certain traditional remedies) can affect liver function.

If liver enzyme elevations are detected, your oncologist may recommend more frequent monitoring or temporary treatment interruption. The SmPC advises caution in patients with severe hepatic impairment; no specific dose reduction is recommended, but interruption or discontinuation may be required if significant hepatotoxicity develops. In most cases, mild enzyme elevations resolve without intervention or with conservative management. Rarely, if significant hepatotoxicity occurs, alternative endocrine therapy options such as tamoxifen or exemestane may be considered.

When to Seek Medical Advice About Anastrozole and Your Liver

Immediate medical attention is warranted if you develop any of the following symptoms whilst taking anastrozole:

• Jaundice – yellowing of your skin or the whites of your eyes

• Severe abdominal pain, particularly in the upper right side

• Dark urine (tea-coloured) combined with pale stools

• Severe nausea and vomiting that prevents you from taking your medication or staying hydrated

• Unexplained bruising or bleeding, which may indicate impaired liver synthetic function

• Confusion or altered mental state, which could suggest severe liver dysfunction

These symptoms require urgent assessment, and you should contact your GP immediately, call NHS 111, or attend your local Emergency Department depending on severity.

Routine medical review is appropriate for:

• Persistent fatigue that seems disproportionate or is worsening

• Mild, persistent abdominal discomfort

• Unexplained itching lasting more than a few days

• Loss of appetite or unintentional weight loss

• General feeling of being unwell without obvious cause

Contact your GP or oncology team within a few days if you experience these symptoms. Do not stop taking anastrozole without medical advice, as this could compromise your cancer treatment.

Pre-existing liver conditions: If you have known liver disease, including fatty liver, hepatitis, or cirrhosis, ensure your oncology team is fully informed. You may require more frequent monitoring. Similarly, if you develop new risk factors for liver disease during treatment (such as significant weight gain, new diagnosis of diabetes, or starting potentially hepatotoxic medications), discuss these with your healthcare team.

Your oncology team will typically schedule regular follow-up appointments that include blood tests. Attend these appointments as scheduled, and always report any new or concerning symptoms between appointments. Early detection and management of liver problems can usually prevent serious complications whilst allowing you to continue benefiting from your cancer treatment.

Reporting side effects: If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the patient information leaflet. You can also report side effects directly via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by downloading the Yellow Card app. By reporting side effects, you can help provide more information on the safety of this medicine.

Frequently Asked Questions